Changing the standard of care in 2nd line recurrent cervical cancer-Recording

Video Transcription

Video Summary

Dr. Brian Slomovitz presented the results of the Innovative 301 trial, a phase 3 study evaluating the efficacy and safety of tezotamab vidotin (TV) in the second or third-line treatment of recurrent or metastatic cervical cancer. The trial enrolled 502 patients who were randomized to receive either TV or investigative choice chemotherapy. The primary endpoint of overall survival was met, with a statistically significant 30% reduction in the risk of death in the TV arm compared to the control arm. TV also demonstrated improvements in progression-free survival and overall response rate. The safety profile of TV was manageable, with adverse events consistent with previous experience. The study concluded that TV should be considered a potential new standard of care for patients with recurrent or metastatic cervical cancer who have progressed after first-line systemic therapy. The results highlight the need for more effective treatment options in this patient population.

Keywords

Dr. Brian Slomovitz

Innovative 301 trial

tezotamab vidotin

cervical cancer

recurrent or metastatic

second or third-line treatment